Hung LY, Alves ND, Del Colle A, Talati A, Najjar SA, Bouchard V, Gillet V, Tong Y, Huang Z, Browning KN, Hua J, Liu Y, Woodruff JO, Juarez D, Medina M, Posner J, Tonello R, Yalcinkaya N, Israelyan N, Ringel R, Yang L, Leong KW, Yang M, Sze JY, Savidge T, Gingrich J, Shulman RJ, Gershon MD, Ouellet A, Takser L, Ansorge MS, Margolis KG (2025) Intestinal epithelial serotonin as a novel target for treating disorders of gut-brain interaction and mood. Gastroenterology 168(4):754-768. doi: 10.1053/j.gastro.2024.11.012 PMID: 39672518
Objective: To investigate how intestinal epithelial serotonin influences mood and gastrointestinal function, and to identify gut-targeted therapies for mood disorders and disorders of gut-brain interaction (DGBI).
Summary: Selective deletion of the serotonin transporter (SERT) from the intestinal epithelium reduced anxiety- and depression-like behaviors in mice without affecting gut motility or cognition. These effects were dependent on afferent vagal signaling. Conversely, depleting intestinal serotonin increased anxiety. A human birth cohort study linked in utero SSRI/SNRI exposure to a higher risk of functional constipation, supporting a gut-brain role in DGBI.
Usage: CCK-SAP (IT-31) was bilaterally injected into the nodose ganglia, and after one week, tests of anxiety and depression were performed.
Related Products: CCK-SAP (Cat. #IT-31)